Is anyone attending this? Looks like there are lots of interesting things that will be happening there:
https://apha.confex.com/apha/141am/webprogram/ATOD.html
https://apha.confex.com/apha/141am/webprogram/postersATOD.html
Especially this:
https://apha.confex.com/apha/141am/webprogram/Paper295582.html
[h=2]Update from the fda's center for tobacco products
[/h]Monday, November 4, 2013 : 11:30 AM - 11:50 AM
Mitchell Zeller, J.D. , Center for tobacco Products, Food and Drug Administration, Rockville, MD
The evolution in the marketplace for tobacco and nicotine over the past decade poses profound questions for FDA now that it is regulating tobacco products. Under the public health standard that is central to key provisions in the Family Smoking Prevention and Tobacco Control Act, FDA has to assess the net population level health impacts of new products and potential health-related claims for these products. This presentation will explain that new standard and describe the most relevant provisions of the Act. The opportunity for an agency-wide comprehensive nicotine regulatory policy will also be reviewed. Finally, recent regulatory actions by FDA will be explained.
https://apha.confex.com/apha/141am/webprogram/ATOD.html
https://apha.confex.com/apha/141am/webprogram/postersATOD.html
Especially this:
https://apha.confex.com/apha/141am/webprogram/Paper295582.html
[h=2]Update from the fda's center for tobacco products
[/h]Monday, November 4, 2013 : 11:30 AM - 11:50 AM
Mitchell Zeller, J.D. , Center for tobacco Products, Food and Drug Administration, Rockville, MD
The evolution in the marketplace for tobacco and nicotine over the past decade poses profound questions for FDA now that it is regulating tobacco products. Under the public health standard that is central to key provisions in the Family Smoking Prevention and Tobacco Control Act, FDA has to assess the net population level health impacts of new products and potential health-related claims for these products. This presentation will explain that new standard and describe the most relevant provisions of the Act. The opportunity for an agency-wide comprehensive nicotine regulatory policy will also be reviewed. Finally, recent regulatory actions by FDA will be explained.